Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Bal PharmaBOM:524824 +4.22%65 Pretax Margin % is 3.83% as of Mar. 2026, which is 136% above its 10-year median of 1.62. GuruFocus rates BOM:524824 with a GF Score™ of 65/100 and a GF Value™ of ₹97.37 (Fairly Valued). The stock has 7 warning signs investors should review. Among 959 Drug Manufacturers companies, Bal Pharma ranks worse than 63.5% on this metric.
Pre-Tax margin is calculated as Pre-Tax Income divided by its Revenue. Bal Pharma's Pre-Tax Income for the
three
months ended in Mar. 2026 was ₹32 Mil. Bal Pharma's Revenue for the
three
months ended in Mar. 2026 was ₹841 Mil. Therefore, Bal Pharma's pretax margin for the quarter that ended in Mar. 2026 was 3.83%.
The historical rank and industry rank for Bal Pharma's Pretax Margin % or its related term are showing as below:
BOM:524824'
s Pretax Margin % Range Over the Past 10 Years
Min: -8.07 Med: 1.62 Max: 3.28
Current: 1.9
BOM:524824's Pretax Margin % is ranked worse than 63.5% of 959
companies
in the Drug Manufacturers industry
Industry Median: 7.29
vs BOM:524824: 1.90
Bal Pharma (BOM:524824) Pretax Margin % Explanation
The pretax margin, as know as pretax profit margin, is widely used to measure the operating efficiency of a company before deducting taxes.
The pretax margin is sometimes preferred over the net margin as tax expenditures can make profitability comparisons between companies misleading.
It is a useful tool to compare companies operating in the same sector and less effective when comparing companies from other sectors as each industry generally has different operating expenses and sales patterns.
The long term trend of the pretax margin is a good indicator of the competitiveness and health of the business.
Bal Pharma Pretax Margin % Related Terms
Bal Pharma Pretax Margin % Historical Data
* Premium members only.
The historical data trend for Bal Pharma's Pretax Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BOM:524824 vs ZTS, UTHR: Pretax Margin % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Bal Pharma's Pretax Margin %, along with its competitors' market caps and Pretax Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Bal Pharma Pretax Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Bal Pharma's Pretax Margin % distribution charts can be found below:
* The bar in red indicates where Bal Pharma's Pretax Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Bal Pharma (BOM:524824) has a Pretax Margin % of 3.83% as of Mar. 2026. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Bal Pharma and its competitors. This is 136% above median its historical median of 1.62. According to the industry distribution chart, Bal Pharma ranks #609 out of 959 companies in the Drug Manufacturers industry, placing it in the top 63.5%.
Is Bal Pharma's Pretax Margin % too high?
Bal Pharma's current Pretax Margin % of 3.83% is 136% above median its 10-year median of 1.62. The Drug Manufacturers industry median Pretax Margin % is 7.29. Bal Pharma's value of 3.83% is 47.5% below this industry median. Based on the distribution chart, Bal Pharma ranks #609 out of 959 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Bal Pharma has a GF Score™ of 65/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Bal Pharma's Pretax Margin % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Bal Pharma ranks #609 out of 959 companies for Pretax Margin %. This places Bal Pharma in the lower half of its industry. The industry median Pretax Margin % is 7.29. Bal Pharma's value of 3.83% is 47.5% below this benchmark. While the company's 10-year median is 1.62 vs. the industry median of 7.29, Bal Pharma has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Pretax Margin % for a Drug Manufacturers company?
The median Pretax Margin % among Drug Manufacturers companies is 7.29, based on 959 companies in the industry. Companies in the top quartile (top 25%) have a Pretax Margin % significantly above this median, while those in the bottom quartile fall well below. However, Pretax Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Bal Pharma's current Pretax Margin % of 3.83% is 47.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Pretax Margin % mean?
A high Pretax Margin % can signal that a stock is expensive relative to its fundamentals. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Bal Pharma and its competitors. For the Drug Manufacturers industry, the median Pretax Margin % is 7.29 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Bal Pharma's current Pretax Margin % is 3.83%, which is 136% above median its own 10-year median of 1.62. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bal Pharma stock overvalued right now?
Based on GuruFocus' analysis, Bal Pharma (BOM:524824) is currently considered Fairly Valued. The stock's GF Value™ is ₹97.37, compared to a current price of ₹90.72 — trading 6.8% below its estimated fair value. The current Pretax Margin % is 3.83%, which is 136% above median its 10-year median of 1.62 and 47.5% below the Drug Manufacturers industry median of 7.29. Bal Pharma's overall GF Score™ is 65/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Pretax Margin % calculated?
Pretax Margin % is calculated from a company's financial statements. For Bal Pharma (BOM:524824), the current Pretax Margin % is 3.83% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Bal Pharma (BOM:524824) Overvalued in 2026?
Based on GuruFocus' analysis, Bal Pharma stock appears to be undervalued.
The current stock price of ₹90.72 is trading 6.8% below its estimated GF Value™ of ₹97.37.
GuruFocus considers Bal Pharma to be Fairly Valued.
Key valuation signals for BOM:524824:
Pretax Margin %: 3.83% (136% above median its 10-year median of 1.62)
GF Value™: ₹97.37 vs. price of ₹90.72 (6.8% below fair value)
Industry Position: 47.5% below the Drug Manufacturers median (#609 of 959)
No single metric tells the full story. See the BOM:524824 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Bal Pharma Ltd is a pharmaceutical company. It is principally engaged in the manufacturing and marketing of pharmaceutical formulations and active pharmaceutical ingredients. The company specializes in prescription drugs, generic and over-the-counter products, intravenous infusion, and bulk actives.
65GF Score
Get the complete analysis for BOM:524824
Pretax Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:524824 has been successfully added to your 
